WILEY
1) Role of Endocrine Responsiveness and HER2/neu Overexpression in Inflammatory Breast Cancer Treated with Multimodality Preoperative Therapy
D'Alessandro C, Dellapasqua S, Orlando L, Santoro L, Maisonneuve P, Torrisi R, Balduzzi A, Scarano E, Ghisini R, Peruzzotti G, Goldhirsch A, Colleoni M.
The Breast Journal (2008), Vol 14, Iss 5, p 435–441
- DOI:
http://dx.doi.org/10.1111/j.1524-4741.2008.00619.x
Yung-Tang Nien, Kun-Ming Chen, In-Gann Chen
Journal of the American Ceramic Society(2010), Vol 93, Iss 6, p 1688–1691
- DOI:
http://dx.doi.org/10.1111/j.1551-2916.2010.03624.x
3) Ten-year outcome after combined modality therapy for inflammatory breast cancer
Eleanor E. R. Harris, Delray Schultz, Helaine Bertsch, Kevin Fox, John Glick and Lawrence J. Solin
International Journal of Radiation Oncology*Biology*Physics(2003), Vol 55, Iss 5, P 1200-1208
- DOI:
http://dx.doi.org/10.1016/S0360-3016(02)04201-3
Kakuya Kitagawa, Koichiro Yamakado, Atsuhiro Nakatsuka, Naoshi Tanaka, Kaname Matsumura, Kan Takeda and Yoshifumi Kawarada
European Journal of Radiology(2002), Vol 43, Iss 1, Pages 31-36
- DOI:
http://dx.doi.org/10.1016/S0720-048X(01)00417-X